A new zebrafish model to study balance issues in progressive supranuclear palsy
A Phenotype-Optimized Zebrafish Model of Progressive Supranuclear Palsy
This study is exploring a new way to understand progressive supranuclear palsy (PSP) by using zebrafish to mimic the brain changes that happen in this condition, which could help researchers find better treatments for people with PSP.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10764950 on NIH RePORTER |
What this research studies
This research investigates progressive supranuclear palsy (PSP), a neurodegenerative disease that causes severe balance problems and other neurological symptoms. The team is developing a zebrafish model that mimics the Tau protein pathology associated with PSP, allowing for better understanding and evaluation of potential treatments. By using zebrafish, which are small and have easily observable behaviors, researchers aim to link the underlying biological mechanisms of balance deficits to the symptoms experienced by patients. The model will be validated through various neurological and behavioral tests to ensure its relevance to human PSP.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with progressive supranuclear palsy who experience significant balance issues.
Not a fit: Patients with other neurodegenerative diseases that do not involve Tau pathology may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve balance and reduce falls in patients with progressive supranuclear palsy.
How similar studies have performed: Previous research has shown promise in using animal models to study neurodegenerative diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Schoppik, David — New York University School of Medicine
- Study coordinator: Schoppik, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.